Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Corcept Therapeutics's total debt was $0 at Dec 31, 2017. For fiscal 2017 it was $0, down 100.0% from the year before. The highest annual figure on record is $35.07M in fiscal 2013.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | -100.0% |
| FY2016 | Dec 31, 2016 | $14.66M | -46.7% |
| FY2015 | Dec 31, 2015 | $27.49M | -18.9% |
| FY2014 | Dec 31, 2014 | $33.89M | -3.4% |
| FY2013 | Dec 31, 2013 | $35.07M | +10.7% |
| FY2012 | Dec 31, 2012 | $31.68M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017 | Dec 31, 2017 | $0 | -100.0% |
| Q3 FY2017 | Sep 30, 2017 | $0 | -100.0% |
| Q2 FY2017 | Jun 30, 2017 | $4.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.66M | – |
| Q3 FY2016 | Sep 30, 2016 | $18.73M | – |
See a number that looks wrong?